These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39252401)

  • 21. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
    Ioannou A; Patel RK; Razvi Y; Porcari A; Sinagra G; Venneri L; Bandera F; Masi A; Williams GE; O'Beara S; Ganesananthan S; Massa P; Knight D; Martinez-Naharro A; Kotecha T; Chacko L; Brown J; Rauf MU; Manisty C; Moon J; Lachmann H; Wechelakar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
    Circulation; 2022 Nov; 146(22):1657-1670. PubMed ID: 36325894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis.
    Nagy D; Révész K; Peskó G; Varga G; Horváth L; Farkas P; Tóth AD; Sepp R; Vágó H; Nagy AI; Masszi T; Pozsonyi Z
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Native T1 mapping in transthyretin amyloidosis.
    Fontana M; Banypersad SM; Treibel TA; Maestrini V; Sado DM; White SK; Pica S; Castelletti S; Piechnik SK; Robson MD; Gilbertson JA; Rowczenio D; Hutt DF; Lachmann HJ; Wechalekar AD; Whelan CJ; Gillmore JD; Hawkins PN; Moon JC
    JACC Cardiovasc Imaging; 2014 Feb; 7(2):157-65. PubMed ID: 24412190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
    Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
    PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valve disease in cardiac amyloidosis: an echocardiographic score.
    Aimo A; Fabiani I; Maccarana A; Vergaro G; Chubuchny V; Pasanisi EM; Petersen C; Poggianti E; Giannoni A; Spini V; Taddei C; Castiglione V; Passino C; Fontana M; Emdin M; Venneri L
    Int J Cardiovasc Imaging; 2023 Oct; 39(10):1873-1887. PubMed ID: 37341947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.
    Poterucha TJ; Elias P; Bokhari S; Einstein AJ; DeLuca A; Kinkhabwala M; Johnson LL; Flaherty KR; Saith SE; Griffin JM; Perotte A; Maurer MS
    JACC Cardiovasc Imaging; 2021 Jun; 14(6):1221-1231. PubMed ID: 33221204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis.
    Cheng RK; Levy WC; Vasbinder A; Teruya S; De Los Santos J; Leedy D; Maurer MS
    JACC CardioOncol; 2020 Sep; 2(3):414-424. PubMed ID: 33073249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
    Kim MM; Prasad M; Burton Y; Kolseth CM; Zhao Y; Chandrashekar P; Nazer B; Masri A
    J Am Heart Assoc; 2023 Aug; 12(15):e029705. PubMed ID: 37522238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.
    Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D
    Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis.
    Ioannou A; Nitsche C; Porcari A; Patel RK; Razvi Y; Rauf MU; Martinez-Naharro A; Venneri L; Accietto A; Netti L; Bandera F; Virsinskaite R; Kotecha T; Knight D; Petrie A; Whelan C; Wechalekar A; Lachmann H; Hawkins PN; Gillmore JD; Fontana M
    J Am Heart Assoc; 2024 Feb; 13(4):e033094. PubMed ID: 38314569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
    Castano A; Haq M; Narotsky DL; Goldsmith J; Weinberg RL; Morgenstern R; Pozniakoff T; Ruberg FL; Miller EJ; Berk JL; Dispenzieri A; Grogan M; Johnson G; Bokhari S; Maurer MS
    JAMA Cardiol; 2016 Nov; 1(8):880-889. PubMed ID: 27557400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population: A Pilot Study.
    Singal AK; Bansal R; Singh A; Dorbala S; Sharma G; Gupta K; Saxena A; Bhargava B; Karthikeyan G; Ramakrishnan S; Bisoi AK; Hote MP; Rajashekar P; Chowdhury UK; Devagourou V; Patel C; Ray R; Arawa SK; Mishra S
    JACC CardioOncol; 2021 Oct; 3(4):565-576. PubMed ID: 34746852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the diagnosis and management of amyloid cardiomyopathy.
    Nijst P; Tang WW
    Fac Rev; 2021; 10():31. PubMed ID: 33817700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep Learning-Enabled Quantification of
    Miller RJH; Shanbhag A; Michalowska AM; Kavanagh P; Liang JX; Builoff V; Fine NM; Dey D; Berman DS; Slomka PJ
    J Nucl Med; 2024 Jul; 65(7):1144-1150. PubMed ID: 38724278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.
    Rauf MU; Hawkins PN; Cappelli F; Perfetto F; Zampieri M; Argiro A; Petrie A; Law S; Porcari A; Razvi Y; Bomsztyk J; Ravichandran S; Ioannou A; Patel R; Starr N; Hutt DF; Mahmood S; Wisniowski B; Martinez-Naharro A; Venneri L; Whelan C; Roczenio D; Gilbertson J; Lachmann HJ; Wechalekar AD; Rapezzi C; Serenelli M; Massa P; Caponetti AG; Ponziani A; Accietto A; Giovannetti A; Saturi G; Sguazzotti M; Gagliardi C; Biagini E; Longhi S; Fontana M; Gillmore JD
    Eur Heart J; 2023 Jun; 44(24):2187-2198. PubMed ID: 36946431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions.
    Genovesi D; Vergaro G; Giorgetti A; Marzullo P; Scipioni M; Santarelli MF; Pucci A; Buda G; Volpi E; Emdin M
    JACC Cardiovasc Imaging; 2021 Jan; 14(1):246-255. PubMed ID: 32771577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
    García-Pavía P; García-Pinilla JM; Lozano-Bahamonde A; Yun S; García-Quintana A; Gavira-Gómez JJ; Aibar-Arregui MÁ; Barge-Caballero G; Núñez Villota J; Bernal L; Tarilonte P
    Rev Esp Cardiol (Engl Ed); 2024 Jul; ():. PubMed ID: 39089574
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
    ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.